SkinBioTherapeutics (SBTX) Competitors GBX 14.44 -0.56 (-3.71%) As of 08/20/2025 11:35 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock SBTX vs. CIR, BVXP, 4BB, SCLP, TILS, VSN, OBI, MPH, HVO, and ORPHShould you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Scancell (SCLP), Tiziana Life Sciences (TILS), Verseon (VSN), Ondine Biomedical (OBI), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry. SkinBioTherapeutics vs. Its Competitors Circassia Group Bioventix 4basebio Scancell Tiziana Life Sciences Verseon Ondine Biomedical Mereo BioPharma Group plc (MPH.L) hVIVO Open Orphan Circassia Group (LON:CIR) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Do insiders and institutionals have more ownership in CIR or SBTX? 16.6% of SkinBioTherapeutics shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CIR or SBTX more profitable? Circassia Group has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -237.95%. Circassia Group's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Circassia GroupN/A N/A N/A SkinBioTherapeutics -237.95%-115.86%-61.18% Which has preferable valuation and earnings, CIR or SBTX? Circassia Group has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCircassia Group£27.90M0.00N/A£0.01N/ASkinBioTherapeutics£1.56M21.14-£3.71M-£1.63-8.88 Does the media prefer CIR or SBTX? In the previous week, SkinBioTherapeutics had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for Circassia Group. SkinBioTherapeutics' average media sentiment score of 0.68 beat Circassia Group's score of 0.00 indicating that SkinBioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Circassia Group Neutral SkinBioTherapeutics Positive SummaryCircassia Group beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks. Get SkinBioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£33.00M£139.28M£5.73B£3.20BDividend YieldN/A3.74%4.45%5.04%P/E Ratio-8.883.9030.37165.53Price / Sales21.144,098.00391.11310,183.61Price / Cash9.0013.1937.0327.94Price / Book8.6048.418.946.00Net Income-£3.71M-£90.99M£3.26B£5.89B7 Day Performance3.17%1.53%-0.11%52.84%1 Month Performance-13.25%4.87%3.15%48.75%1 Year Performance17.48%188.87%27.35%106.46% SkinBioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSkinBioTherapeuticsN/AGBX 14.44-3.7%N/A+16.8%£33.00M£1.56M-8.8811Gap UpCIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,408-3.7%N/A-43.7%£126.09M£13.65M15.5712Gap Down4BB4basebioN/AGBX 943-5.7%GBX 1,600+69.7%-32.6%£120.80M£311K-1,208.97101SCLPScancellN/AGBX 11.15+1.4%N/A-38.2%£115.48MN/A-17.0951Positive NewsTILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60M-3.5911VSNVerseonN/AN/AN/AN/A£112.24MN/A-5.17N/AGap UpOBIOndine BiomedicalN/AC$13.00flatN/A+146.5%C$93.47MC$48.60K-3.92N/ANews CoverageGap DownMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownHVOhVIVO2.5068 of 5 starsGBX 10.85+5.9%GBX 28+158.1%-66.3%£76.77M£68.74M4.48N/AGap UpORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179 Related Companies and Tools Related Companies Circassia Group Alternatives Bioventix Alternatives 4basebio Alternatives Scancell Alternatives Tiziana Life Sciences Alternatives Verseon Alternatives Ondine Biomedical Alternatives Mereo BioPharma Group plc (MPH.L) Alternatives hVIVO Alternatives Open Orphan Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:SBTX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SkinBioTherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share SkinBioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access